Troutman Pepper advised Innervace on the deal.Innervace, a regenerative medicine company developing the first implantable biofabricated neural pathway to restore brain circuitry, announced its $40 million…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
